Rebecca is a senior associate in the Patents and Innovation Group. She advises clients on contentious patent matters and the commercialisation of intellectual property.
Rebecca has litigated in the High Court, Court of Appeal, and at the UK IPO. She regularly works on multi-jurisdictional cases and has particular experience advising clients in the life sciences and telecoms sectors. Prior to qualifying as a solicitor Rebecca worked in the life sciences sector, negotiating clinical trials and R&D related contracts.
by multiple authors
Revocation of life sciences patents in the UPC
The Unified Patent Court (UPC), active since June 2023, is seeing strong uptake in pharma and biotech. Revocation decisions show a balanced 50:50 win rate for patentees and challengers. Key legal standards on novelty, obviousness, and inventive step are emerging, though some aspects remain unclear. Strategic use of the UPC offers broad enforcement, but revocation risks are higher for single-patent portfolios. Legal uncertainties, like the Bolar exemption, still need clarification.
by Lydia Birch and Rebecca Limer
4 of 5 Insights
by multiple authors
by Dr. Benedikt Kohn, CIPP/E and Alexander Schmalenberger, LL.B.
by multiple authors
by multiple authors
by Oli Denne and Shane Gleghorn
by Irina Rebin
by Irina Rebin
by Irina Rebin and Daniel Dietrich
by multiple authors